{
    "id": "heart_failure_sglt2_inhibitors_selectAll_v1",
    "type": "selectAll",
    "stem": "The nurse is providing education for a client with Heart Failure with Reduced Ejection Fraction (HFrEF) who is being started on an SGLT2 inhibitor (e.g., dapagliflozin). Which instructions are essential for the safe use of this medication?",
    "options": [
        {
            "id": "a",
            "text": "Monitor specifically for signs of genital fungal (yeast) infections."
        },
        {
            "id": "d",
            "text": "Decrease potassium intake, as this drug can cause hyperkalemia."
        },
        {
            "id": "c",
            "text": "Maintain adequate fluid intake to prevent dehydration."
        },
        {
            "id": "b",
            "text": "Report any symptoms of a urinary tract infection (UTI) immediately."
        },
        {
            "id": "f",
            "text": "Contact the provider for severe nausea and abdominal pain (risk of euglycemic DKA)."
        },
        {
            "id": "e",
            "text": "Perform daily foot checks and report any new sores or ulcers."
        }
    ],
    "correctOptionIds": [
        "a",
        "b",
        "c",
        "e",
        "f"
    ],
    "pedagogy": {
        "bloomLevel": "apply",
        "cjmmStep": "takeAction",
        "nclexCategory": "Pharmacological and Parenteral Therapies",
        "difficulty": 4,
        "topicTags": [
            "Pharmacology",
            "Heart Failure",
            "Endocrine"
        ]
    },
    "rationale": {
        "correct": "SGLT2 inhibitors are now a pillar of HFrEF therapy. (A & B) Since the drug causes glycosuria (sugar in urine), it increases the risk for fungal and bacterial infections in the GU tract. (C) They have a mild diuretic effect, increasing dehydration risk. (E) There is a known increased risk of lower limb amputations/ulcers with some SGLT2s. (F) Euglycemic DKA—ketoacidosis with relatively normal glucose—is a rare but life-threatening side effect.",
        "incorrect": "(D) SGLT2 inhibitors do not generally cause hyperkalemia; this is more characteristic of ACE inhibitors, ARBs, or Spironolactone, which are often used *with* SGLT2s but are a different class logic.",
        "answerBreakdown": [
            {
                "label": "A",
                "content": "Selecting \"Monitor specifically for signs of genital fungal (yeast) infections.\" is evidence-based as it directly correlates with the primary clinical cues and pathophysiology.",
                "isCorrect": true
            },
            {
                "label": "B",
                "content": "Selecting \"Decrease potassium intake, as this drug can cause hyperkalemia.\" might delay more critical interventions, as it does not address the immediate life-threatening risk.",
                "isCorrect": false
            },
            {
                "label": "C",
                "content": "Selecting \"Maintain adequate fluid intake to prevent dehydration.\" is evidence-based as it directly correlates with the primary clinical cues and pathophysiology.",
                "isCorrect": true
            },
            {
                "label": "D",
                "content": "The inclusion of \"Report any symptoms of a urinary tract infection (UTI) immediately.\" is necessary to address the underlying physiological instability identified during assessment.",
                "isCorrect": true
            },
            {
                "label": "E",
                "content": "Selecting \"Contact the provider for severe nausea and abdominal pain (risk of euglycemic DKA).\" is evidence-based as it directly correlates with the primary clinical cues and pathophysiology.",
                "isCorrect": true
            },
            {
                "label": "F",
                "content": "Clinically, \"Perform daily foot checks and report any new sores or ulcers.\" is the most appropriate finding pointing toward the suspected condition and requiring intervention.",
                "isCorrect": true
            }
        ],
        "clinicalPearls": [
            "SGLT2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death regardless of the presence of diabetes."
        ],
        "questionTrap": {
            "trap": "The 'Diabetes Only' Assumption",
            "howToOvercome": "Remember that SGLT2s (the '-gliflozins') are now cardiac drugs. Don't be surprised to see them in a Heart Failure question, but the side effects (yeast/UTI/DKA) remain the same."
        },
        "mnemonic": {
            "title": "F-L-O-Z-I-N",
            "expansion": "Fungal infections, Low volume (Dehydration), Organs (DKA risk), Zero sugar (in blood - it's in the urine!), Insist on foot checks."
        },
        "reviewUnits": [
            {
                "heading": "SGLT2 Inhibitors in Heart Failure",
                "body": "Dapagliflozin and Empagliflozin promote glucose and sodium excretion in the proximal tubule. This reduces preload and afterload. Key nursing focus: Perineal hygiene and metabolic acidosis monitoring.",
                "source": "ACC/AHA HF Guidelines 2026"
            }
        ]
    },
    "scoring": {
        "method": "polytomous",
        "maxPoints": 5
    }
}